|
Title
|
Published
|
Price
|
|
Monoclonal antibodies: 2009 update
By: Datamonitor
Introduction The report provides a comprehensive financial and strategic analysis of the mAb market, forecasting its commercial evolution out to 2014 and assessing trends by product, company, therapy area, geography, technology and target type. It also
|
more...
|
11/2/2009
|
$7,600.00
|
|
Freedonia Focus on Biologicals
By: Freedonia Focus
This report discusses US biologicals demand for the years 2003 and 2008, with forecasts for 2013. Topics covered include market size, product and market segmentation, technological and product development, regulatory considerations, market environment,
|
more...
|
10/31/2009
|
$500.00
|
|
Regenerative Medicines: Bone and Joint Applications
By: BCC Research
REPORT HIGHLIGHTS
Overall sales in the regenerative medicine productsmarket were worth $1.1 billion in 2007, and remained flat into 2009. By 2014, sales are projected to increase to nearly $1.8 billion, for a
|
more...
Search inside this report
|
10/1/2009
|
$4,850.00
|
|
Forecast Insight: Top 20 Cancer Therapy Brands Targeted therapies will drive market growth in the wake of the cytotoxic and antihormonal patent cliff
By: Datamonitor
Introduction
The cancer therapies market offers a high level of commercial reward to a handful of companies including Roche, Sanofi-Aventis, AstraZeneca, Novartis and Eli Lilly. Cancer therapy sales totaled over $38 billion in the seven
|
more...
|
9/22/2009
|
$15,200.00
|
|
Bioarrays for Life Science Research, Diagnostics and Drug R&D
By: Takeda Pacific
This research report is about the worldwide bioarray tools, technologies and services market. Bioarrays are also known as DNA microarrays, protein arrays, or biochips. These key mainstream life science research products and services involve technologies
|
more...
|
8/1/2009
|
$2,495.00
|
|
Expanding Applications of Personalized Medicine: Use of Biomarkers in Prognostic, Predictive and Pharmacogenetic Tests in a Targeted Approach
By: Business Insights
Introduction
Against a background of increasing commercial pressures the need to find new markets and exploit them has never been greater. At the same time changes in prevailing healthcare thinking with respect to the
|
more...
Search inside this report
|
8/1/2009
|
$3,835.00
|
|
Monoclonal Antibodies: Pipeline Analysis and Competitive Assessment
By: CHI Insight Pharma Reports
In the nearly 35 years since the first process for creating mAbs was introduced, they have remained a centerpiece of the growing biotechnology industry. Thirty therapeutic mAbs have been approved around the world, including
|
more...
|
8/1/2009
|
$3,750.00
|
|
Competitor Analysis: Immunotoxins
By: La Merie S.L.
The present Competitive Intelligence Report about Immunotoxins provides a competitor evaluation in the field of tumor targeted toxins by means of antibodies or proteins for treatment of cancer as of July 2009.
Immunotoxin
|
more...
Search inside this report
|
7/1/2009
|
$210.00
|
|
Targeted Drug Delivery Technologies: Players, products & prospects to 2018 (Volume IV)
By: Espicom Healthcare Intelligence
This major strategic analysis provides a detailed insight into the current and future market for targeted drug delivery technology.
|
more...
Search inside this report
|
6/26/2009
|
$1,130.00
|
|
Monoclonal Antibody Therapeutics 2009-2024
By: Visiongain
Monoclonal antibodies achieved total sales of nearly $32bn in 2008 and have grown rapidly to command over 30% of the global biologic drug market. We expect significant opportunities for further commercial growth from 2009 to
|
more...
|
6/8/2009
|
$2,502.00
|
|
Competitor Analysis: Immunocytokines
By: La Merie S.L.
The present Competitive Intelligence Report about Immunocytokines provides a competitor evaluation in the field of tumor targeted cytokines by means of antibodies, proteins, peptides and other carriers for treatment of cancer as of June 2009.
|
more...
Search inside this report
|
6/1/2009
|
$212.66
|
|
Competitor Analysis: Antibody-Drug Conjugates (ADC)
By: La Merie S.L.
The present Competitive Intelligence Report about Antibody-Drug Conjugates (ADC) / Immunoconjugates provides a competitor evaluation in the field of tumor targeting antibodies conjugated with a drug payload for treatment of cancer as of June 2009.
|
more...
Search inside this report
|
6/1/2009
|
$354.43
|
|
Therapeutic Monoclonal Antibodies Markets
By: Trimark Publications
Antibodies are proteins in the immune system that help the body defend against foreign invasion, particularly from pathogens and toxins. As such, a human-engineered therapeutic monoclonal antibody (mAb) is protein derived from the immune system
|
more...
|
6/1/2009
|
$1,999.00
|
|
Monoclonal Antibodies in Cancer Therapy 2009-2024
By: Visiongain
Monoclonal antibodies in cancer therapy - significant commercial opportunities with developing technologies and innovative products - our new report explains prospects
Monoclonal antibody-based therapies for cancer are a thriving part of the biotechnology sector,
|
more...
|
5/7/2009
|
$2,502.00
|
|
The Market for Antibodies: Keys to Success for Commercial Suppliers, Vol. III
By: BioInformatics, LLC
The Market for Antibodies: Keys to Success for Commercial Suppliers, Volume III, is part three of BioInformatics LLC’s on-going analysis of the market for antibodies. One thousand scientists completed a 35-question survey fielded
|
more...
|
5/1/2009
|
$5,200.00
|
|
The World Market for Cancer Therapeutics and Biotherapeutics, 3rd. Edition
By: Kalorama Information
Worldwide cancer affects more than 10 million people each year. This number is expected to increase by 2.4% by 2020 to 14 million each year. Worldwide approximately 22 million people are living with
|
more...
Search inside this report
|
5/1/2009
|
$3,995.00
|
|
Dealmaking and Industry Outlook: Therapeutic Antibodies and Vaccines for Cancer
By: Decision Resources
Introduction
Targeted cancer therapies have achieved phenomenal growth, and many MAb-based immunotherapies are blockbusters
or mega-blockbusters. This market success is due not only to these MAbs’ ability to treat unmet need in
many cancers but
|
more...
|
4/9/2009
|
$2,250.00
|
|
Competitor Analysis: CEA Antibodies
By: La Merie S.L.
The present Competitive Intelligence Report about CEA Antagonists provides a competitor evaluation in the field of investigational antibodies and vaccines targeting carcinoembryonic antigen (CEA) for treatment of cancer as of April 2009.
|
more...
Search inside this report
|
4/7/2009
|
$70.00
|
|
Competitor Analysis: EpCAM Antagonists
By: La Merie S.L.
The present Competitive Intelligence Report about EpCAM Antagonists provides a competitor evaluation in the field of investigational antibodies and antibody-based constructs targeting epithelial cell adhesion molecule (EpCAM) for treatment of cancer as of April 2009.
|
more...
Search inside this report
|
4/1/2009
|
$140.00
|
|
Antibody Report: Market Overview and Industry Survey - Premium
By: Biocompare
The 2009 Antibody Report is composed of an in-depth overview of the Antibody Market and the results of the 2009 Antibody Survey. The survey explores topics such as antibody usage, antibody pricing, and purchase behavior
|
more...
|
3/24/2009
|
$4,500.00
|
|
Antibody Report: Market Overview and Industry Survey - Basic
By: Biocompare
The 2009 Antibody Report is composed of an in-depth overview of the Antibody Market and the results of the 2009 Antibody Survey. The survey explores topics such as antibody usage, antibody pricing, and purchase behavior
|
more...
Search inside this report
|
3/24/2009
|
$3,500.00
|
|
Competitor Analysis: CD22 Antibodies
By: La Merie S.L.
The present Competitive Intelligence Report about anti-CD22 antibody-based constructs used to treat B-cell mediated malignancies and rheumatoid arthritis provides a competitor evaluation in the field of R&D projects with anti-CD22 antibodies as of January 2009.
|
more...
Search inside this report
|
1/26/2009
|
$105.00
|
|
Competitor Analysis: CD30 Antibodies
By: La Merie S.L.
The present Competitive Intelligence Report about anti-CD30 antibody-based constructs used to treat lymphomas provides a competitor evaluation in the field of R&D projects with anti-CD30 antibodies as of January 2009. The report includes
|
more...
Search inside this report
|
1/26/2009
|
$70.00
|
|
Competitor Analysis: CD20 Antibodies
By: La Merie S.L.
The present Competitive Intelligence Report about anti-CD20 antibodies used to treat B-cell mediated malignancies and rheumatoid arthritis provides a competitor evaluation in the field of R&D projects with anti-CD20 antibodies as of January 2009.
|
more...
Search inside this report
|
1/25/2009
|
$275.00
|
|
Analytical Tool - The Commercial Success of Cancer Therapeutic Antibodies
By: BioSeeker Group AB
Executive Summary
"Analytical Tool - Cancer Therapeutic Antibodies" offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in antibody drug development for the treatment of cancer. It is
|
more...
|
1/20/2009
|
$5,740.00
|
|
Title
|
Published
|
Price
|
(0 items)
